| 2.9198 0.07 (2.45%) | 06-15 12:50 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 3.59 | 1-year : | 4.2 |
| Resists | First : | 3.07 | Second : | 3.59 |
| Pivot price | 2.8  |
|||
| Supports | First : | 2.64 | Second : | 2.36 |
| MAs | MA(5) : | 2.71 |
MA(20) : | 2.76 |
| MA(100) : | 2.52 |
MA(250) : | 2.4 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 58 |
D(3) : | 37 |
| RSI | RSI(14): 58.7 |
|||
| 52-week | High : | 3.22 | Low : | 1.79 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ SPRO ] has closed below upper band by 23.7%. Bollinger Bands are 7.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.85 - 2.87 | 2.87 - 2.88 |
| Low: | 2.67 - 2.68 | 2.68 - 2.7 |
| Close: | 2.82 - 2.85 | 2.85 - 2.87 |
Spero Therapeutics, Inc. is a biopharmaceutical firm in the clinical development stage, primarily focused on discovering, advancing, and commercializing innovative treatments for multi-drug resistant (MDR) bacterial infections and rare diseases within the United States. The company's pipeline includes several key therapeutic candidates: tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic designed to address complicated urinary tract infections (cUTIs), including pyelonephritis, in adult patients. SPR206, an intravenously administered agent specifically developed to combat MDR Gram-negative bacterial infections in hospital environments. SPR720, an oral antibiotic targeting non-tuberculous mycobacterial (NTM) pulmonary disease. Spero Therapeutics has also forged several strategic alliances: A licensing agreement with Meiji Seika Pharma Co., Ltd. supports the ongoing development of tebipenem HBr. A separate licensing deal with Everest Medicines grants rights for the development, manufacturing, and commercialization of SPR206 across Greater China, South Korea, and various Southeast Asian nations. The company collaborates with the Bill & Melinda Gates Medical Research Institute to advance SPR720 for treating lung infections caused by Mycobacterium tuberculosis. Furthermore, a licensing agreement with Vertex Pharmaceuticals Incorporated covers patents associated with SPR720 and its active metabolite, SPR719. Founded in 2013, Spero Therapeutics maintains its corporate headquarters in Cambridge, Massachusetts.
Thu, 11 Jun 2026
SPRO News | SPERO THERAPEUTICS INC (NASDAQ:SPRO) - ChartMill
Mon, 08 Jun 2026
Spero Therapeutics: Approval Upside, Commercial Friction (Initiating Hold) - Seeking Alpha
Wed, 13 May 2026
Spero Therapeutics (SPRO) trims Q1 2026 loss ahead key tebipenem FDA date - Stock Titan
Wed, 13 May 2026
Is Spero Therapeutics (SPRO) 110.3% Overvalued After Q1 2026 Ear - GuruFocus
Wed, 06 May 2026
Spero Therapeutics CEO sells $63,352 in company stock - Investing.com
Thu, 26 Mar 2026
Spero’s oral UTI antibiotic faces FDA decision on June 18 - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 58 (M) |
| Held by Insiders | 4.652e+007 (%) |
| Held by Institutions | 22.5 (%) |
| Shares Short | 1,180 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 24.8 % |
| Operating Margin | -2 % |
| Return on Assets (ttm) | 921.7 % |
| Return on Equity (ttm) | 12.9 % |
| Qtrly Rev. Growth | 6.119e+007 % |
| Gross Profit (p.s.) | -65.48 |
| Sales Per Share | 24.05 |
| EBITDA (p.s.) | 2.28904e+007 |
| Qtrly Earnings Growth | 0.2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 7 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0.12 |
| Price to Cash Flow | 4.08 |
| Dividend | 0 |
| Forward Dividend | 1.71e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|